PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7988021

Restandardized IMx CA 125 assay: does reference interval need readjustment?

C Beyer·E G Lentjes·D J Stoeken
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

CA-125 AntigenFemaleHumansOvarian NeoplasmsReagent Kits, DiagnosticReference ValuesLetter

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C Beyer, E G Lentjes, D J Stoeken. 1994. Restandardized IMx CA 125 assay: does reference interval need readjustment?. https://pubmed.ncbi.nlm.nih.gov/7988021/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

Effects of endometriomas on ooccyte quality, embryo quality, and pregnancy rates in in vitro fertilization cycles: a prospective, case-controlled study.

PURPOSE: The effect of endometriomas on oocyte quality, embryo quality, and pregnancy rates in in vitro fertilization (IVF) cycles was evaluated. METHODS: Forty-five women had "chocolate" cysts aspirated at the time of oocyte retrieval, and cyst fluid CA 125 levels were measured to ascertain presence of "true" endometriomas. Fifty-seven women without any complex cysts at the time of oocyte retrieval served as controls. IVF cycle outcome parameters were compared between the two groups. RESULTS: Women with endometriomas experienced a significantly higher rate of early pregnancy loss compared to controls (47 vs 14%). There was also a trend toward fewer oocytes retrieved and fewer embryos reaching at least the four-cell stage 48 hr after retrieval in patients with true endometriomas vs controls. CONCLUSIONS: The presence of endometriomas at the time of oocyte retrieval is associated with increased rates of early pregnancy losses. The number of oocytes retrieved and the embryo quality may also be affected adversely in the presence of endometriomas.

CA-125 Antigen↗
PubMed1998

Serum and cystic fluid levels of soluble interleukin-2 receptor-alpha in patients with epithelial ovarian tumors are correlated.

At the diagnosis of ovarian cancer, patients have higher serum levels of soluble interleukin-2 receptor-alpha (IL-2R alpha) compared to patients with benign ovarian tumors or healthy blood donors (means of 750 vs. 469 and 390 U/ml, respectively, p < 0.001). Serum levels were positively related to the extent of the disease. Disease progression was associated with rising serum levels of IL-2R alpha in 13 of the 15 patients but no advantage was recognized over serum CA 125 measurements when following the effect of therapy. We measured higher levels of IL-2R alpha in cystic fluids from epithelial ovarian cancers compared to benign ovarian tumors (means of 1,620 and 616 U/ml, respectively, p = 0.0002). In ovarian cancer patients, serum levels at diagnosis were positively correlated to cystic fluid levels (p < 0.0001). The presence of high IL-2R alpha levels in cystic fluids from epithelial ovarian cancer may provide a biochemical signal of lymphocyte activation at the tissue level.

CA-125 Antigen↗